ENLIVEN THERAPEUTICS, INC. Increase (Decrease) in Other Operating Assets
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Increase (Decrease) in Other Operating Assets of $60.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2022-03-15
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in other operating assets for the quarter ending 2020-12-31 was $0.00.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in other operating assets for the quarter ending 2020-09-30 was $0.00.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in other operating assets for the quarter ending 2019-12-31 was -$369.00K.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in other operating assets for fiscal 2020 was $60.00K, a 31.82% decline from fiscal 2019.
- ENLIVEN THERAPEUTICS, INC. increase (decrease) in other operating assets for fiscal 2019 was $88.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $60.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $60.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $60.00K 10-Q · filed 2021-08-06 | |||
| 2019-12-31 | -$369.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $88.00K 10-K · filed 2021-03-05 | ||
| 2019-09-30 | $457.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |